Regeneron (REGN) drug pricing deal lowers costs, offers free therapy

AI Summary

Regeneron (REGN) agreed to lower U.S. drug prices as part of a deal with President Trump, allowing for the first hearing-loss gene therapy to be offered for free to eligible U.S. patients following FDA approval. This agreement is part of a broader initiative involving 17 deals with pharmaceutical companies aimed at aligning U.S. drug prices with those in other developed nations. Regeneron's gene therapy, Otarmeni, has been projected to achieve peak sales of $130 million, offering significant potential market impact. The deal also includes a three-year exemption from tariffs on pharmaceutical products, which may influence pricing strategies.